checkAd

     104  0 Kommentare The Power Play by the Market Herald Releases New Interviews With Lumiera, Fsd Pharma, HydroGraph, and Adastra Holdings

    VANCOUVER, BC / ACCESSWIRE / December 2, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Lumiera, FSD Pharma, HydroGraph, and Adastra Holdings discussing their latest press releases.The Power Play by The …

    VANCOUVER, BC / ACCESSWIRE / December 2, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Lumiera, FSD Pharma, HydroGraph, and Adastra Holdings discussing their latest press releases.

    The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.

    Lumiera (TSXV:NHP) ends fiscal year on a high note with strong sales in November

    Lumiera Health (NHP) recorded a 30 per cent increase in Q4 2021 versus Q4 2020. The company saw a 59 per cent sales increase in November 2021 versus November 2020. Sales for the year increased by 10 per cent over 2020.Carlos Ponce, CEO of Lumiera Health sat down with Caroline Egan to discuss the results. Lumiera Health specializes in the development and commercialization of consumer products for the natural health industry

    For the full interview with Carlos Ponce and to learn more about Lumiera's fiscal year results, click here.

    FSD Pharma (CSE:HUGE) demonstrates positive effects of Lucid-MS in treating MS in pre-clinical models

    FSD Pharma (HUGE) is sharing pre-clinical data demonstrating the potentially disease-modifying effects of its lead drug candidate Lucid-MS in mice. Lucid-MS is a patented neuroprotective new chemical entity (NCE) that affects protein citrullination and myelin structure. The company has released a video explaining its pre-clinical results, including visual evidence of functional recovery on pre-clinical subjects. Anthony Durkacz, interim CEO at FSD Pharma sat down with Caroline Egan to discuss Lucid-MS and the exciting visual evidence shown in the video.

    For the full interview with Anthony Durkacz and to learn more about FSD Pharma's Lucid-MS drug trial, click here.

    HydroGraph Clean Power (CSE:HG) begins trading on the CSE

    Common shares of HydroGraph Clean Power (HG) have commenced trading on the CSE effective December 2 under the symbol HG. The hydrogen and graphene markets represent a combined market opportunity of C$282 billion by 2030. HydroGraph fulfilled the requirements for the release of $6.5 million held in trust from its brokered subscription receipt financing. COO Kjirstin Breure sat down with Caroline Egan to discuss the listing and provide information on the company.

    Seite 1 von 3



    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    The Power Play by the Market Herald Releases New Interviews With Lumiera, Fsd Pharma, HydroGraph, and Adastra Holdings VANCOUVER, BC / ACCESSWIRE / December 2, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Lumiera, FSD Pharma, HydroGraph, and Adastra Holdings discussing their latest press releases.The Power Play by The …